U.S. equities closed lower on Tuesday, May 19, 2026, as another move higher in long‑term yields pressured the AI‑heavy growth complex and extended the market’s pullback from recent record highs.markets.
Closing levels and performance
The major U.S. indices finished in the red, giving back a portion of their strong year‑to‑date advances as the bond market re‑priced the “higher for longer” rate narrative.
- S&P 500: closed around 7,353.61, down roughly 0.67% on the day.
- Dow Jones Industrial Average: finished near 49,363.88, off about 0.65% as rate sensitivity and profit‑taking weighed on blue chips.
- Nasdaq Composite: ended the session .84% lower at 25,870.71, underperforming the S&P 500 as semiconductor and broader growth shares remained under pressure; intraday quotes showed the index down close to 1%.
Even with today’s declines, year‑to‑date gains remain sizable: recent data show the S&P 500 up just over 8%, the Dow higher by roughly 3% and the Nasdaq ahead by more than 12% for 2026.
Macro and rates backdrop
Today’s selling was once again anchored in the bond market, where the 10‑year Treasury held in the mid‑4% range and the 30‑year hovered above 5%, near the highest levels since 2023. That move in the long end keeps pressure on equity multiples, particularly for long‑duration growth assets whose valuations are most sensitive to the discount rate.
Recent global macro outlooks continue to flag a regime of moderate growth and sticky inflation into 2026, leaving central banks with little room to deliver the kind of aggressive easing cycle that equity bulls had hoped for earlier in the year. Inflation‑linked indicators in bond markets still suggest price growth staying above pre‑pandemic norms, a dynamic that has helped push term premia higher and contributed to the latest leg up in yields.
Sector dynamics and AI trade
The AI and semiconductor complex remained the fulcrum of today’s equity weakness. After a powerful run that helped drive record highs in the Nasdaq and S&P 500 earlier this month, chipmakers and high‑multiple software names extended their pullback as investors questioned how much future AI growth is already discounted in prices. With bond yields marching higher, the market’s tolerance for long‑dated narratives has narrowed, and flows have rotated incrementally toward value and defensive franchises with nearer‑term cash‑flow visibility.
Energy shares softened alongside a modest downtick in crude, which eased after recent geopolitical‑driven spikes but remains elevated versus levels seen earlier this year. That small reprieve on oil helps at the margin on the inflation front, but traders remain acutely focused on headline risk from the Middle East given its direct feed‑through into inflation expectations and rate pricing..
Takeaways for your readers
Today’s tape fits the pattern of a rate‑driven reset rather than a wholesale unwind of the bull market. With the S&P 500 and Nasdaq still up firmly year‑to‑date, higher long‑end yields are forcing investors to:
- Re‑underwrite positions in AI and semis with a sharper focus on earnings visibility, capital intensity, and timeline to cash returns.
- Rebalance portfolios away from pure duration trades and toward quality balance sheets and steady free‑cash‑flow generators that can justify their multiples in a 4–5% yield world.
- Watch yield curves and breakeven inflation as the primary referees for equity valuations from here, with each move in the long end likely to dictate whether pullbacks present opportunities or signal a more extended consolidation phase.
VP Watchlist Updates
Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.
InMed Pharmaceuticals’ (NASDAQ: INM, $1.60, +135.05%)
InMed Pharmaceuticals’ planned merger with Mentari Therapeutics reads less like a struggling micro-cap pivot and more like a biotech coming‑of‑age story set against a trillion‑dollar headache: migraine. If the deal closes as outlined, a once‑overlooked cannabinoid platform could become the Nasdaq wrapper for one of the more ambitious next‑gen migraine franchises now making its way toward the clinic.
Amwell® (NYSE: AMWL, $7.83, +.90%)
Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-
enabled healthcare platform, highlighted (May 18) results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.
Amwell announced (May 5) financial results for the first quarter ended Mar. 31, 2026.
“Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”
FMC Corporation (NYSE: FMC, $12.76)
FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share (roughly 2.26%), payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.
Eupraxia Pharmaceuticals (EPRX, $6.29)
Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.
Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.
Modular Medical (MODD, $3.33)
- Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, saw (May 1) CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
- Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
- Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.
The InterGroup Corporation (INTG, $37.29)
- InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.
Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO, +10.99%)
- Volato Group, Inc. (NYSE American: SOAR) (the “Company” or “Volato”) announced (May 18) that its pro-forma cash balance was $5.5 million at March 31, 2026. This pro-forma cash balance equates to $0.14 cash per share. The pro-forma calculation includes cash raised in April from its now completed ATM Prospectus Supplement filed on March 30, 2026.
- Volato Group, Inc. (NYSE American: SOAR) recently announced voting results indicate that the shareholders have approved the previously announced merger with M2i Global, Inc. (“M2i Global”)(OTCQB: MTWO) with 99% of the shares of common stock present or represented by valid proxy at the special meeting voting in favor of the merger. This marks a significant milestone toward closing the transaction and advancing Volato’s strategic expansion into the critical minerals sector. The number of shares of common stock present or represented by valid proxy at the special meeting was 15.1 million, representing approximately 40% of the total number of shares of common stock entitled to vote. Management believes that the approval reflects strong shareholder alignment with the Company’s strategic direction and long-term growth plans.
Nokia (NOK, $13.67)
- Nokia is quietly turning the humble home router into a mini network strategist, and Wall Street is starting to notice. NVIDIA’s billion‑dollar bet on the Finnish vendor in 2025 only sharpened that narrative, tying living‑room Wi‑Fi to the coming 6G, AI‑native era. Nokia has rolled out “agentic AI” for home and broadband networks, aiming to move consumer connectivity from reactive trouble‑ticket handling to proactive, autonomous optimization. Instead of waiting for a frustrated customer to reboot the router, Nokia’s software layer watches traffic patterns, anticipates congestion, and adjusts in real time to keep streaming, gaming, and video calls on track. The company describes agentic AI as a paradigm where AI systems set and pursue goals with limited or no human intervention, making decisions continuously rather than executing one‑off predictions. In practice, that means fleets of micro‑agents embedded in broadband platforms like Corteca and other access software, each tasked with jobs such as fault isolation, congestion management, or quality‑of‑experience tuning.
NVIDIA (NVDA, $220.61)
NVIDIA CEO Jensen Huang is working through significant regulatory headwinds by joining President Trump’s delegation to China in an effort to repair trade ties after a dramatic collapse in the company’s China revenue, which previously made up a substantial portion of its data center business. Although the U.S. authorized H200 chip sales to 10 Chinese companies in late 2025, demand has remained soft as Chinese buyers have been reluctant to commit.
NVIDIA will host a conference call on Wednesday, May 20, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the first quarter of fiscal year 2027, which ended April 26, 2026. The call will be webcast live (in listen-only mode) on investor.nvidia.com.
McDonald’s (MCD, $280.80)
- Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .
Tesla (TSLA, $404.11)
Tesla’s latest reveal reads a bit like a family group chat gone public—over $500 million in revenue tied to Elon Musk’s own empire, because apparently vertical integration now includes your boss’s other companies. Meanwhile, the solar business is having a cloudy moment, robotics competition is heating up, and just to keep things interesting, Tesla snagged a jaw-dropping 370 Semi order. Oh, and in case that wasn’t enough, there’s talk of a casual $119 billion chip manufacturing push—because why not add semiconductors to the to-do list?
Serina Therapeutics (NYSE: SER, $1.61)
Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, reported (May 14) its financial results for the first quarter ended March 31, 2026, along with key business updates. The company highlighted the follow: Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 & Closed $21.2 million private placement financing to support continued advancement of SER-252. “With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”
Everspin (MRAM, $31.72)
Chandler, AZ’s Everspin’s (MRAM) new $40 million defense pact reads less like a routine semiconductor contract and more like a carefully scripted act in Washington’s ongoing bid to onshore critical tech—with an Arizona memory specialist unexpectedly cast in a leading role.
BuzzFeed, Inc. (BZFD, $1.31)
BuzzFeed, Inc. (NASDAQ: BZFD) has entered into a transaction agreement with Allen Family Digital, LLC, an affiliate of Byron Allen’s family office, that would see Allen invest $120 million for a majority stake in the once high-flying digital media pioneer. Under the deal, Allen’s vehicle will purchase 40 million shares at $3.00 apiece, giving it roughly 52% of BuzzFeed’s outstanding shares when the transaction closes.
GeoVax Labs (GOVX, $2.01, +46.72% over the last 5-days)
A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the ground, companies from micro-cap GeoVax to blue-chip Merck (MRK, $114.24, +1.49%) and Johnson & Johnson (JNJ, $230.00 +.47%) are jostling—politely—for a role in turning cutting-edge science into boots-on-the-ground protection.
The Sources
- Yahoo Finance – Stock Market News for May 18, 2026
https://finance.yahoo.com/markets/stocks/articles/stock-market-news-may-18-120100990.htmlfinance.yahoo - Yahoo Finance – Live Market Coverage (Stocks)
https://finance.yahoo.com/markets/stocks/live/stock-market-today-monday-may-18-earnings-nvidia-232705005.htmlfinance.yahoo - CNBC – Stock Market Today: Live Updates
https://www.cnbc.com/2026/05/17/stock-market-today-live-updates.htmlthestreet - Charles Schwab – Stock Market Update
https://www.schwab.com/learn/story/stock-market-update-openschwab - Edward Jones – Daily Market Snapshot
https://www.edwardjones.com/us-en/market-news-insights/stock-market-news/daily-market-recapedwardjones - J.P. Morgan Asset Management – Weekly Market Recap (PDF)
https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/insights/market-insights/wmr/weekly_market_recap.pdfjpmorgan - Federal Reserve – Summary of Economic Projections (March 2026, PDF)
https://www.federalreserve.gov/monetarypolicy/files/fomcprojtabl20260318.pdffederalreserve - IMF – World Economic Outlook, April 2026
https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026imf - Nvidia – Q4 & Fiscal 2026 Financial Results
https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-fourth-quarter-and-fiscal-2026nvidianews.nvidia - Nvidia – Events & Presentations (Earnings, IR)
https://investor.nvidia.com/events-and-presentations/events-and-presentations/default.aspxinvestor.nvidia - Fortune – Current Price of Oil as of May 18, 2026
https://fortune.com/article/price-of-oil-05-18-2026/fortune - Democracy Now – Headlines for May 18, 2026 (War & Geopolitics)
https://www.democracynow.org/2026/5/18/headlinesdemocracynow
